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Objective: The pharmacokinetics of amrubicin in patients with impaired hepatic function have not been
reported. The aim of this study was to compare the pharmacokinetics of amrubicin and its major me-
tabolite, amrubicinol, and to assess the safety of amrubicin in lung cancer patients with impaired hepatic
function and those with normal hepatic function.
Materials and methods: Five patients with impaired hepatic function (arm I) and 10 patients with normal
hepatic function (arm N) with small or non-small cell lung carcinoma were enrolled. Liquid chromato-
graphy with tandem mass spectrometry was used to determine the amrubicin and amrubicinol con-
centrations. Pharmacokinetic parameters were estimated by non-compartmental analysis.
Results: The terminal half-lives of amrubicin and amrubicinol in whole blood and plasma were slightly
longer in arm I than in arm N. The area under the concentration–time curve (AUC0–24h) values of am-
rubicin in plasma and AUC0–120h of amrubicinol in whole blood in arm I were not larger than those in arm
N because of dose adjustments based on prior treatment history and baseline values of total bilirubin,
aspartate aminotransferase and alanine aminotransferase. The dose-normalized AUCs (dose 40 mg/m2)
of amrubicin and amrubicinol in arm I were slightly larger than those in arm N. There were two deaths in
arm I, one related to disease progression and one from an unknown cause.
Conclusion: If an adjusted dose of amrubicin is used in patients with impaired hepatic function, the
exposure of amrubicin and amrubicinol would be within the range of variation observed in patients with
normal hepatic function.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Ltd. This is an open access article u
aspartate aminotransferase;
, Eastern Cooperative Oncol-
in
Information Center, number
Masuda).1. Introduction
Amrubicin, a totally synthetic 9-amino-anthracycline and po-
tent inhibitor of DNA topoisomerase II, is converted to its active
13-hydroxy metabolite, amrubicinol, through the reduction of its
C-13 ketone group to a hydroxy group by the action of cytoplasmic
carbonyl reductase in liver, kidney, and tumor tissues [1]. In pre-
clinical studies, amrubicin has been found to exert more potentnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Criteria for hepatic function and selecting the amrubicin dose.
Amrubicin dose (mg/m2/day) 1st-line/
2nd-line or more
AST or ALT (baseline)
WNL 4ULN to
r2.5ULN
42.5ULN
T-bil (baseline) WNL 45/40 a 40/35 b
4ULN to
r1.5ULN
35/30 b
41.5ULN to
r3.0ULN
– 35/30 b 30/25 b
AST, aspartate aminotransferase; ALT, alanine aminotransferase; T-bil, total bilir-
ubin; WNL, within normal limits; ULN, upper limit of normal.
a Normal hepatic function (arm N).
b Impaired hepatic function (arm I).
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human tumor xenografts implanted in nude mice [2]. Amrubicin
does not cause typical anthracycline cardiotoxicity [3].
The dose of doxorubicin, an anthracycline drug, in patients with
impaired hepatic function is usually decreased based on serum
bilirubin or aspartate aminotransferase (AST) concentrations be-
cause plasma doxorubicin concentrations are reportedly increased
in these patients [4–6]. Anthracyclines should therefore be care-
fully administered to patients with liver dysfunction for safety
reasons. The pharmacokinetics of amrubicin and amrubicinol have
been reported for patients with normal hepatic function but not
for patients with impaired hepatic function [7]. Therefore, we
evaluated the pharmacokinetics of amrubicin and amrubicinol,
and the safety of amrubicin in lung cancer patients with or
without impaired hepatic function. We also assessed the validity
of amrubicin dose adjustment based on hepatic function.2. Materials and methods
2.1. Patient selection
Eligibility criteria included the presence of histologically or
cytologically proven SCLC or NSCLC, Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0–2, 20–70 years of age,
life expectancy of at least 1 month, and no evidence of hepatitis B
virus infection. Patients were required to have adequate organ
function, a white blood cell count between 4000/μL and 12,000/
μL, neutrophil count Z2000/μL, platelet count Z10.0104/μL,
hemoglobin level Z8.0 g/dL, serum creatinine concentration
r1.5 mg/dL, partial pressure of arterial oxygen Z70 mmHg, and
no abnormal electrocardiogram requiring treatment.
Exclusion criteria included symptomatic brain metastases, un-
controlled diabetes (hemoglobin A1c Z8.0%), massive pericardial
or pleural effusion requiring drainage, superior vena cava syn-
drome, gastric or duodenal ulcer, severe heart disease, interstitial
pneumonia or pulmonary ﬁbrosis as shown by chest radiography.
Pregnant or nursing women were also excluded.
This study was approved by the institutional review board of
each site and was conducted in accordance with the Declaration of
Helsinki and guidelines on good clinical practice. All patients gave
written informed consent prior to entering this study. This study
was registered with the Japan Pharmaceutical Information Center,
number JapicCTI-122036.
2.2. Dosage and drug administration
The dose of amrubicin was adjusted from 25 to 45 mg/m2/day
(iv, days 1–3, q3w) based on prior treatment history and baseline
values of total bilirubin (T-bil), AST and alanine aminotransferase
(ALT) (Table 1). The number of treatment cycles was at least one
cycle (21 days) and a maximum of four cycles.
2.3. Pharmacokinetic evaluation
Concentrations of amrubicin and amrubicinol in plasma and
whole blood were determined and their pharmacokinetic para-
meters were evaluated on cycle 1, as described in the Supple-
mentary information.
Liquid chromatography with tandem mass spectrometry was
used to determine the amrubicin and amrubicinol concentrations
in human whole blood, plasma and samples for protein binding.
All analytical methods were validated, and all samples were ana-
lyzed at JCL Bioassay Corporation (Hyogo, Japan).
Non-compartmental analysis was used to determine the fol-
lowing pharmacokinetic parameters for amrubicin andamrubicinol: area under the concentration–time curve from 0 to
24 h (AUC0–24h), terminal half-life (t1/2) and total clearance of
amrubicin on day 1, area under the concentration–time curve from
0 to 120 h (AUC0–120h) and t1/2 of amrubicinol on day 3.
The dose-normalized AUCs (AUC0–24h of amrubicin and AUC0–
120h of amrubicinol) in patients with impaired hepatic function
(arm I) were estimated to compare amrubicin and amrubicinol
exposure in whole blood or plasma between patients in arm I and
patients with normal hepatic function (arm N). The dose-nor-
malized AUCs were estimated by the following equation:
Dose-normalized AUC ¼ AUC0–24h of amrubicin and AUC0–120h
of amrubicinol40/dose of each patient in arm I.
In the phase 1 clinical study, amrubicin and amrubicinol con-
centrations in blood cells or plasma were evaluated at doses from
10 to 130 mg. In this dose range, amrubicin and amrubicinol
concentrations (AUCs) in blood cells or plasma were well corre-
lated with dose, and the AUC levels in the phase 1 study covered
the AUC range in this study [7]. Therefore, the AUCs of amrubicin
and amrubicinol were normalized by the dose ratio.
2.4. Safety evaluation
Adverse events were graded according to the Common Termi-
nology Criteria for Adverse Events version 3.0.3. Results
3.1. Patients
Five patients in arm I and ten patients in arm N were enrolled
between January 2010 and December 2012 at nine participating
sites. The demographic and baseline patient characteristics are
shown in Table 2. The doses of amrubicin in arm I and arm N were
25–35 mg/m2/day and 40 mg/m2/day, respectively.
3.2. Pharmacokinetic analysis
All 15 patients received amrubicin on days 1–3. Full whole
blood and plasma samples were collected for pharmacokinetic
analysis. Whole blood and plasma concentration–time curves of
amrubicin and amrubicinol are shown in Fig. 1, and the pharma-
cokinetic parameters of each patient in arm I and in arm N are
shown in Table 3. A comparison of exposure (AUC) of amrubicin
and amrubicinol between arm N and arm I is shown in Fig. 2.
Amrubicin concentrations in whole blood and plasma were simi-
lar, and amrubicinol concentrations in whole blood were higher
than those in plasma. Whole blood and plasma concentration
proﬁles of amrubicin and amrubicinol were similar between the
Table 2
Patient and disease characteristics.
Patient No. Amrubicin dose (mg/m2) Age Sex Tumor type PS Liver metastasis Albumin (mg/dL) Hepatic function (baseline)
AST (IU/L) ALT (IU/L) T-bil (mg/dL)
Arm I
PK-01 35 63 M NSCLC (3rd-line) 2 No 3.0 75 196 0.4
PK-02 25 54 M SCLC (2nd-line) 2 Yes 3.4 303 137 2.1
PK-03 25 66 M SCLC (2nd-line) 1 Yes 3.5 105 71 2.8
PK-04 35 54 F NSCLC (2nd-line) 2 Yes 2.4 108 131 0.4
PK-05 30 55 M SCLC (1st-line) 1 Yes 3.1 472 284 2.8
Arm N
PK-06 40 67 M NSCLC (3rd-line) 0 No 4.2 23 28 0.8
PK-07 40 62 M NSCLC (2nd-line) 0 No 3.8 19 12 0.3
PK-08 40 55 M NSCLC (2nd-line) 1 No 3.1 20 13 0.23
PK-09 40 58 M NSCLC (3rd-line) 1 No 4.5 32 13 0.2
PK-10 40 70 M SCLC (3rd-line) 1 No 4.6 39 51 0.5
PK-11 40 58 M NSCLC (6th-line) 1 No 3.9 48 30 0.8
PK-12 40 48 M NSCLC (2nd-line) 1 No 3.7 21 27 0.33
PK-13 40 64 M SCLC (2nd-line) 1 No 3.8 18 13 0.4
PK-14 40 61 M NSCLC (5th-line) 1 No 3.4 53 28 0.3
PK-15 40 66 M SCLC (2nd-line) 0 No 4.5 24 31 0.5
Arm I, impaired hepatic function; Arm N, normal hepatic function; PS, performance status; T-bil, total bilirubin; AST, aspartate aminotransferase; ALT, alanine amino-
transferase; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer.
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high whole blood and plasma concentrations of amrubicin at 24 h
after the infusion on day 3 compared with those observed in the
remaining patients, but the reason for this was unclear (Fig. 1).
The pharmacokinetic parameters of amrubicin and amrubicinol
are shown in Table 3. The AUC0–24h of amrubicin and AUC0–120h of
amrubicinol in arm I were not larger than those in arm N because
of dose adjustments based on prior treatment history and baseline
values of T-bil, AST and ALT. The mean t1/2 of amrubicin in arm I
was signiﬁcantly longer than that in arm N in whole blood and
plasma (p¼0.0158 and p¼0.0215, respectively). However, the
difference was not large (approximately 0.6 h). Clearance of am-
rubicin in whole blood and plasma was not statistically different
between the two arms, although it seemed to slightly decrease in
arm I. In addition, the t1/2 of amrubicinol and amrubicin in whole
blood and plasma in arm I was somewhat longer than that in arm
N. One patient in arm I (PK-04) showed a longer t1/2 than those
observed in the remaining arm I patients.
Comparisons of exposure (AUC) of amrubicin and amrubicinol
between arm I and arm N were conducted. Because doses in arm I
differed by patient, AUCs in arm I were normalized at a dose of
40 mg/m2. The dose-normalized AUCs of amrubicin in whole blood
and plasma did not differ between the two arms, and dose-nor-
malized AUCs of amrubicinol in whole blood and plasma in arm I
were slightly but signiﬁcantly larger than those in arm N (po0.01,
Fig. 2). The mean AUC in arm I/mean AUC in arm N ratios in whole
blood and plasma were evaluated for each compound. The ratios of
amrubicin in whole blood and plasma were 1.20 and 1.11, respec-
tively, and those of amrubicinol in whole blood and plasma were
1.28 and 1.41, respectively. The ratios of amrubicinol were some-
what larger than those of amrubicin in both whole blood and
plasma.
The difference in dose-normalized AUCs between arm I and
arm N was conducted from the aspect of AUC ratio (amrubicinol/
amrubicin AUC ratio) in whole blood and plasma. The amrubicinol/
amrubicin AUC ratio in whole blood was not different between
arm I and arm N (p¼0.7581); however, the ratio in plasma in arm I
was somewhat larger than that in arm N (p¼0.0515).
The relationship between exposure (AUC) and some re-
presentative parameters of liver function (T-bil, AST and ALT) were
evaluated. The dose-normalized AUCs of amrubicin andamrubicinol, observed in patients with elevated baseline values of
T-bil, AST and ALT, were not correlated with these baseline values
(data not shown).
The protein binding of amrubicin and amrubicinol in arm I
(91.3–97.1% and 82.0–85.3%, respectively) was not different from
that in arm N [95.471.6% and 85.772.2%, respectively
(mean7SD of 10 patients)]. The protein binding of amrubicin and
amrubicinol was not correlated with baseline albumin levels.
3.3. Safety
All 15 patients were evaluated for safety. One or more adverse
drug reactions were observed. The most common grade 3 or worse
drug-related adverse event in arm I was anemia (60%; 3/5 pa-
tients) (Table 4). By contrast, adverse events in arm N were he-
matologic toxicity, especially leukopenia (80%; 8/10 patients) and
neutropenia (80%; 8/10 patients).
Two deaths occurred in arm I. One patient (PK-02; at day 11 in
cycle 1) died from disease progression, and the other (PK-01; at
day 4 in cycle 4) from an unknown cause. The causality between
death and amrubicin in PK-01 was unknown because of in-
sufﬁcient information.4. Discussion
Hepatic impairment potentially increases exposure to drugs
metabolized in the liver [8,9]. It has been reported that the me-
tabolism of amrubicin and amrubicinol is highly dependent on
liver function [10]. Therefore, we evaluated the pharmacokinetics
of amrubicin and amrubicinol and safety in lung cancer patients
with or without impaired hepatic function and assessed the va-
lidity of dose adjustment of amrubicin based on hepatic function.
Because few lung cancer patients with hepatic impairment
satisﬁed the study criteria, our data were limited, and more cases
are needed to conﬁrm the pharmacokinetic properties of amru-
bicin and amrubicinol in patients with hepatic impairment. In
previous studies, most of the amrubicin and amrubicinol con-
centrations measured Z24 h after drug administration could not
be determined because of poor sensitivity of the analytical
method. To determine lower concentrations at later sampling
Fig. 1. Amrubicin and amrubicinol concentration–time curves in whole blood or plasma on days 1 and 3 in each arm. Arm I, impaired hepatic function; Arm N, normal
hepatic function.
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used to measure amrubicin and amrubicinol were improved from
20 ng/mL to 1.05 and 2 ng/mL in whole blood and plasma, re-
spectively. The sensitivity of this method was approximately 10–20
times higher than that previously described [11,12]. In the pre-
vious study, the t1/2 of amrubicin in plasma was 1.76–2.30 h on day
1 and that of amrubicinol in plasma on day 3 was 13.0–18.1 h [12].Because the concentrations at 24 h or later could be determined in
this study, the t1/2 values of amrubicinol (mean t1/2: 40.330 h in
whole blood, 44.535 h in plasma) were longer than those de-
termined in a previous study [11]. In addition, the pharmacoki-
netic proﬁles of amrubicin and amrubicinol were clariﬁed because
of the later sampling point (48–120 h) than that in a previous
study [11,12]. Amrubicin showed biphasic kinetics and
Table 3
Pharmacokinetic parameters of amrubicin and amrubicinol.
Amrubicin Whole blood Plasma
Pharmacokinetic
parameter
AUC0–24h
(ng h/mL)
t1/2 (h) Clearance (L/h/m2) Dose-normal-
ized AUC0–24h
(ng h/mL)
AUC0–24h
(ng h/mL)
t1/2 (h) Clearance (L/h/m2) Dose-normal-
ized AUC0–24h
(ng h/mL)
Arm I PK-01
(35 mg)
1838 4.16 17.49 2101 1960 3.92 16.45 2240
PK-02
(25 mg)
1664 4.42 13.72 2662 2111 4.65 10.77 v
PK-03
(25 mg)
2066 4.10 11.11 3306 2305 3.81 9.99 3689
PK-04
(35 mg)
3270 4.76 9.74 3737 3002 4.23 10.67 3430
PK-05
(30 mg)
2398 4.28 11.48 3197 2504 4.99 10.87 3339
Mean7SD — 4.34370.263a 12.70573.034 3000.77632.2 – 4.32070.494 * 11.74972.648 3215.07561.8
Arm N Mean7SD
(n¼10;
40 mg)
(range)
2497.97663.6 3.88370.306 15.48273.183 AUC ratio a 2902.37717.6 3.74270.324 13.35072.938 AUC ratio a
(1865–4189) (3.44–4.39) (8.81–19.76) 1.20 (2162–4424) (3.23–4.21) (8.34–17.05) 1.11
Amrubicinol Whole blood Plasma
Pharmacokinetic parameter AUC0–120h
(ng h/mL)
t1/2 (h) Dose-normalized AUC0–
120h (ng h/mL)
AUC0–120h
(ng h/mL)
t1/2 (h) Dose-normalized AUC0–
120h (ng h/mL)
Arm I PK-01 (35 mg) 2248 45.54 2569 1139 53.55 1302
PK-02 (25 mg) 1896 42.55 3034 1270 45.87 2032
PK-03 (25 mg) 2203 47.08 3525 1091 51.80 1746
PK-04 (35 mg) 3658 74.32 4180 1457 82.88 1665
PK-05 (30 mg) 2270 38.88 3027 1126 42.02 1501
Mean7SD – 49.673714.129 3267.17612.3 * – 55.222716.134 1649.47273.4 *
Arm N Mean7SD (n¼10;
40 mg) (range)
2550.57304.0 40.33074.007 AUC ratio a 1173.07149.8 44.53574.398 AUC ratio a
(2079–2945) (36.08–46.30) 1.28 (843–1358) (37.88–50.32) 1.41
Arm I, impaired hepatic function; Arm N, normal hepatic function; AUC0–24h, area under the concentration–time curve from 0 to 24 h; AUC0–120h, area under the con-
centration–time curve from 0 to 120 h; dose-normalized AUC, area under the concentration–time curve normalized to the 40 mg/m2 dose; t1/2, terminal half-life.
* po0.01 [t-test was conducted after logarithmic transformation of AUC (dose-normalized AUC in arm I and arm N) and clearance, and after reciprocal transformation for
t1/2 between arm I and arm N].
a AUC ratio ¼ mean dose-normalized AUC in arm I/mean AUC in arm N.
S. Ryuge et al. / Cancer Treatment and Research Communications 9 (2016) 81–87 85comparatively fast elimination; by contrast, amrubicinol showed
biphasic and monophasic kinetics and slow elimination. This
might suggest an innate pharmacokinetic property of amrubicin
and amrubicinol.
Because this was the ﬁrst clinical study to investigate the
pharmacokinetics of amrubicin and amrubicinol in patients with
hepatic impairment, the dose of amrubicin was adjusted from 25
to 45 mg/m2/day based on prior treatment history and baseline
values of T-bil, AST and ALT. In arm I, the AUCs of amrubicin and
amrubicinol in plasma and whole blood were not larger than those
in arm N, and clearance of amrubicin was within the range of
variation of that observed in arm N. The mean t1/2 of amrubicin in
arm I was signiﬁcantly longer than that in arm N in whole blood
and plasma. This may be caused by a slight decrease in clearance
because of hepatic impairment, although clearance of amrubicin in
whole blood and plasma was not statistically different between
the two arms. In addition, t1/2 of amrubicinol and amrubicin in
whole blood and plasma in arm I was slightly longer than that in
arm N. This may be caused by a decrease in metabolic capacity
because of hepatic impairment. One patient in arm I (PK-04)
showed longer t1/2 and larger exposure (AUC) of amrubicin and
amrubicinol compared with those observed in the remaining pa-
tients, although hepatic impairment was mild. Longer t1/2 and
larger exposure (AUC) of amrubicin and amrubicinol were unclear,
but this may be partly explained by a decrease in metabolic ac-
tivity due to a genetic polymorphism of one of the metabolicenzymes of amrubicin and amrubicinol, NADPH:quinone oxidor-
eductase [13]. However, additional investigations will be required
to clarify this phenomenon.
The dose-normalized AUCs of amrubicin and amrubicinol in
plasma and whole blood in arm I were slightly larger than those in
arm N, but the dose-normalized AUCs of amrubicin and amrubi-
cinol, observed in patients with elevated baseline values of T-bil,
AST and ALT, did not correlate with these baseline values. Exposure
in patients with impaired hepatic function might be larger than in
patients with normal liver function. However, because the dose-
normalized AUCs of amrubicin and amrubicinol did not always
correlate with baseline T-bil, AST and ALT, it would be preferable to
adjust the administered dose not only by hepatic function but also
by patient conditions.
The amrubicinol/amrubicin AUC ratios in whole blood did not
differ between arm I and arm N, but the ratios in plasma in arm I
appeared to be larger than those in arm N. This is because in
plasma, the AUCs of amrubicinol in arm I were larger than those in
arm N. Amrubicin distributes in blood cells and plasma equally. By
contrast, amrubicinol distributes more in blood cells than in
plasma. The effect of hepatic impairment on distribution to blood
cells and plasma may be different between amrubicin and amru-
bicinol, but the reasons for this are unclear.
The mean AUC in arm I/mean AUC in arm N ratios in whole
blood and plasma were evaluated for amrubicin and amrubicinol.
The ratios of amrubicinol in whole blood and plasma were larger
Fig. 2. Comparison of exposure (AUCs) of amrubicin and amrubicinol between arm N and arm I. Upper left, amrubicin AUC0–24h in whole blood on day 1. Lower left,
amrubicin AUC0–24h in plasma on day 1. Upper right, amrubicinol AUC0–120h in whole blood on day 3. Lower right, amrubicinol AUC0–120h in plasma on day 3. The dose was
40 mg/m2 in arm N (; n¼10) and was 35 mg/m2 [△(PK-01); ▽(PK-04)], 30 mg/m2 [◇(PK-05)], or 25 mg/m2 [○(PK-02), □(PK-03)] in arm I. The AUC for “arm I dose-normalized”
was normalized at a dose of 40 mg/m2 (n ¼ 5). The top, middle and bottom lines of each box correspond to the 75% (top quartile), 50% (median) and 25% (bottom quartile)
values, respectively. The whiskers show the range of values that fall within one standard deviation; closed circles inside each box show the mean, and asterisks show the
maximum and minimum values. Arm I, impaired hepatic function; Arm N, normal hepatic function. *po0.01 for the dose-normalized AUC in arm I versus arm N.
Table 4
Grade Z3 hematologic and non-hematologic drug-related adverse events.
Grade Arm I (n¼5) Arm N (n¼10)
3 4 5 Z3 (%) 3 4 5 Z3 (%)
No. of patients experiencing hematologic toxicity
Leukopenia 1 0 0 1 (20) 6 2 0 8 (80)
Neutropenia 1 0 0 1 (20) 0 8 0 8 (80)
Lymphopenia 1 1 0 2 (40) 2 0 0 2 (20)
Thrombocytopenia 0 0 0 0 (0) 1 0 0 1 (10)
Anemia 3 0 0 3 (60) 0 0 0 0 (0)
No. of patients experiencing non-hematologic toxicity
Death 0 0 1 1 (20) 0 0 0 0 (0)
Infection 1 0 0 1 (20) 0 0 0 0 (0)
Anorexia 1 0 0 1 (20) 0 0 0 0 (0)
ALP increased 1 0 0 1 (20) 0 0 0 0 (0)
Arm I, impaired hepatic function; Arm N, normal hepatic function; ALP, alkaline phosphatase.
S. Ryuge et al. / Cancer Treatment and Research Communications 9 (2016) 81–8786than those of amrubicin. This may be caused by hepatic impair-
ment on metabolic enzymes. Amrubicin is metabolized by carbo-
nyl reductase; by contrast, amrubicinol is metabolized by NADPH:
quinone oxidoreductase. Enzyme activity of NADPH:quinone oxi-
doreductase was assumed to become less active than that of car-
bonyl reductase in patients with hepatic impairment. Another
reason may be the differences in t1/2. Amrubicin in whole blood
and plasma was eliminated in a biphasic manner, and the elim-
ination half-life (β phase) was comparatively short (approximately
4 h). Amrubicinol in whole blood and plasma was eliminated in amonophasic manner, and the elimination half-life (β phase) was
long (440 h). Even if the t1/2 of amrubicin is slightly lengthened
by hepatic impairment, the effect on the AUC is small. This is be-
cause in the β phase, the concentrations are low in comparison
with the maximum concentration. However, in the case of amru-
bicinol, if the t1/2 is slightly lengthened by hepatic impairment, the
effect on the AUC is large, because in the elimination phase, the
concentrations are relatively higher in comparison with the
maximum concentration.
It has been reported that changes in protein binding affect the
S. Ryuge et al. / Cancer Treatment and Research Communications 9 (2016) 81–87 87concentration of protein-free drug, which is a key factor possibly
related to efﬁcacy, and a patient with impaired hepatic function
may have a decreased ability to produce albumin in the liver [14].
It has also been reported in an in vitro protein binding study that
amrubicin and amrubicinol mainly bind serum albumin [15]. In
this study, we determined the in vivo protein binding of amrubicin
and amrubicinol. The protein binding of amrubicin and amrubi-
cinol in arm I was not different from that in arm N; therefore, the
inﬂuence of protein binding on pharmacokinetics and efﬁcacy of
amrubicin could not be explored. In addition, the results of the
protein binding studies were similar to those of an in vitro protein
binding study (amrubicin: 96.6%, amrubicinol: 89.3% at
2000 ng/mL) [15].
The AUCs of amrubicin and amrubicinol in arm I were not
larger than those in arm N because amrubicin doses were adjusted
to low levels in arm I, which led to a lower incidence of grade
3 leukopenia and neutropenia in arm I compared with arm N.
Although two deaths occurred in arm I, no relationship with
treatment could be established for either.5. Conclusions
This is the ﬁrst report describing the pharmacokinetics of am-
rubicin and amrubicinol in patients with impaired hepatic func-
tion. Although these data are limited, the adjusted amrubicin dose
in patients with impaired hepatic function is useful based on
pharmacokinetic results. Therefore, if the adjusted dose of amru-
bicin in this study is used in clinical practice in patients with im-
paired hepatic function, the exposure of amrubicin and amrubi-
cinol would be within the range of variation in that observed in
patients with normal hepatic function.Conﬂict of interest
Dr. Fukuoka received an advisory fee from Sumitomo Dai-
nippon Pharma Co., Ltd. Dr. Takagaki, Dr. Shono, Dr. Kitagawa, and
Dr. Kurihara are employed by Sumitomo Dainippon Pharma Co.,
Ltd. The other authors have no conﬂicts of interest.Acknowledgments
We thank all of the patients, their families, and independent
data safety monitoring committee members; Dr. Hironobu Minami
(Kobe University Hospital) and Dr. Makoto Nishio (The Cancer
Institute Hospital of Japanese Foundation for Cancer Research);
and all of the amrubicin pharmacokinetic study investigators. We
would also like to thank Dr Nicholas Smith (Edanz Group Ltd.) forproviding editorial support. This study was sponsored by Sumi-
tomo Dainippon Pharma Co., Ltd., Osaka, Japan. The sponsor was
involved in the collection and analysis of data and in the decision
to submit the manuscript for publication.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.ctarc.2016.08.008.References
[1] M. Yamamoto, A. Takakura, N. Masuda, Next-generation anthracycline for the
management of small cell lung cancer: focus on amrubicin, Drug Des. Devel.
Ther. 2 (2009) 189–192.
[2] S. Morisada, Y. Yanagi, T. Noguchi, et al., Antitumor activities of a novel
9-aminoanthracycline (SM-5887) against mouse experimental tumors and
human tumor xenografts, Jpn. J. Cancer Res. 80 (1989) 69–76.
[3] T. Noda, T. Watanabe, A. Kohda, et al., Chronic effects of a novel synthetic
anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced
cardiomyopathy in beagle dogs, Investig. New Drugs 16 (1998) 121–128.
[4] K.K. Chan, R.T. Chlebowski, M. Tong, et al., Clinical pharmacokinetics of
adriamycin in hepatoma patients with cirrhosis, Cancer Res. 40 (1980)
1263–1268.
[5] P.J. Johnson, N. Dobbs, C. Kalayci, et al., Clinical efﬁcacy and toxicity of standard
dose adriamycin in hyperbilirubinaemic patients with hepatocellular carci-
noma: relation to liver tests and pharmacokinetic parameters, Br. J. Cancer 65
(1992) 751–755.
[6] R.G. Morris, P.A. Reece, B.M. Dale, et al., Alteration in doxorubicin and doxor-
ubicinol plasma concentrations with repeated courses to patients, Ther. Drug
Monit. 11 (1989) 380–383.
[7] K. Inoue, M. Ogawa, N. Horikoshi, et al., Phase I and pharmacokinetic study of
SM-5887, a new anthracycline derivative, Investig. New Drugs 7 (1989)
213–218.
[8] M.G. Donelli, M. Zucchetti, E. Munzone, et al., Pharmacokinetics of anticancer
agents in patients with impaired liver function, Eur. J. Cancer 34 (1998) 33–46.
[9] L.J. Schaaf, L.A. Hammond, S.J. Tipping, et al., Phase 1 and pharmacokinetic
study of intravenous irinotecan in refractory solid tumor patients with hepatic
dysfunction, Clin. Cancer Res. 12 (2006) 3782–3791.
[10] N. Tani, M. Yabuki, S. Komuro, H. Kanamaru, Characterization of the enzymes
involved in the in vitro metabolism of amrubicin hydrochloride, Xenobiotica
35 (2005) 1121–1133.
[11] Sumitomo Dainippon Pharma Co., Ltd. Calseds for Injection [Interview form]
(in Japanese). 〈http://www.info.pmda.go.jp/go/interview/2/400093_
4235406D1020_2_013_1F.pdf〉, 2014. (accessed 18.09.15).
[12] Sumitomo Pharmaceuticals Co., Ltd. Calseds (amrubicin hydrochloride)
[Product information] (in Japanese). 〈http://www.pmda.go.jp/drugs/2002/
P200200013/index.html〉, 2002. (accessed 18.09.15).
[13] M. Nagata, T. Kimura, T. Suzumura, et al., C609T polymorphism of NADPH
quinone oxidoreductase 1 correlates clinical hematological toxicities in lung
cancer patients treated with amrubicin, Clin. Med. Insights Oncol. 7 (2013)
31–39.
[14] C.F. Stewart, J.A. Pieper, S.G. Arbuck, W.E. Evans, Altered protein binding of
etoposide in patients with cancer, Clin. Pharmacol. Ther. 45 (1989) 49–55.
[15] S. Nakai, K. Akao, M. Ito, et al., Studies on the metabolic fate of amrubicin
hydrochloride (SM-5887), a novel antitumor agent (I): blood concentration,
distribution, metabolism and excretion after a single intravenous adminis-
tration to rats, Drug Metab. Pharmacokinet. 13 (1998) 61–77 (in Japanese).
